{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:50:30Z","timestamp":1791409830844,"version":"4.3.3"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T2588102"],"award-info":[{"award-number":["T2588102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004517","name":"Tianjin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004517","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110289","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:02:25Z","timestamp":1785250945000},"page":"110289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of molecular glue degrader for treatment of IMiDs-resistant multiple myeloma based on GLUT-mediated tumor targeting strategy"],"prefix":"10.1016","volume":"181","author":[{"given":"Manwei","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110289_bb0005","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2011-09-377846","article-title":"Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy","volume":"119","author":"McBrayer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110289_bb0010","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1021\/acsptsci.1c00074","article-title":"Drug and solute transporters in mediating resistance to novel therapeutics in multiple myeloma","volume":"4","author":"Mynott","year":"2021","journal-title":"ACS Pharmacol. Transl."},{"key":"10.1016\/j.bioorg.2026.110289_bb0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.bioorg.2026.110289_bb0020","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110289_bb0025","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110289_bb0030","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bioorg.2026.110289_bb0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-3-642-54490-3_22","article-title":"Pomalidomide","volume":"201","author":"Engelhardt","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110289_bb0040","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110289_bb0045","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110289_bb0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-016-0540-0","article-title":"Elotuzumab: First global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110289_bb0055","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110289_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bioorg.2026.110289_bb0065","first-page":"562","article-title":"Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma","volume":"35","author":"Fu","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110289_bb0070","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110289_bb0075","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110289_bb0080","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acschemneuro.0c00076","article-title":"GLUT-1: an effective target to deliver brain-derived neurotrophic factor gene across the blood brain barrier","volume":"11","author":"Arora","year":"2020","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.bioorg.2026.110289_bb0085","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0006-291X(88)81333-0","article-title":"Liposome targeting to mouse brain: mannose as a recognition marker","volume":"153","author":"Umezawa","year":"1988","journal-title":"Biochem. Bioph. Res. Co."},{"key":"10.1016\/j.bioorg.2026.110289_bb0090","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the Blood\u2013Brain Barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bioorg.2026.110289_bb0095","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s12035-015-9672-6","article-title":"Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery","volume":"54","author":"Patching","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2026.110289_bb0100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.bioorg.2026.110289_bb0105","first-page":"1599","article-title":"Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment","volume":"6","author":"Labak","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110289_bb0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.leukres.2015.12.008","article-title":"Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents","volume":"41","author":"Matsumoto","year":"2016","journal-title":"Leukemia Res."},{"key":"10.1016\/j.bioorg.2026.110289_bb0115","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1039\/D0OB00216J","article-title":"Synthesis of artemisinic acid derived glycoconjugates and their anticancer studies","volume":"18","author":"Kotammagari","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2026.110289_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041748","article-title":"In vitro and in vivo efficacy of a novel glucose\u2013methotrexate conjugate in targeted cancer treatment","volume":"22","author":"Wo\u017aniak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110289_bb0125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bmcl.2006.11.008","article-title":"Synthesis of 2\u2032-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells","volume":"17","author":"Liu","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110289_bb0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbrc.2017.04.004","article-title":"Mannose-conjugated platinum complexes reveals effective tumor targeting mediated by glucose transporter 1","volume":"487","author":"Liu","year":"2017","journal-title":"Biochem. Bioph. Res. Co."},{"key":"10.1016\/j.bioorg.2026.110289_bb0135","doi-asserted-by":"crossref","first-page":"39476","DOI":"10.18632\/oncotarget.17073","article-title":"GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110289_bb0140","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.2024025861","article-title":"Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma","volume":"145","author":"Chrisochoidou","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110289_bb0145","article-title":"A Degron blocking strategy towards improved CRL4CRBN recruiting PROTAC selectivity","volume":"24","author":"Bouguenina","year":"2023","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bioorg.2026.110289_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110289_bb0155","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2174\/0109298673382742250619055201","article-title":"Targeted protein degradation in lung Cancer: the emerging role of PROTAC technology and E3 ligases","volume":"33","author":"Hussain","year":"2026","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110289_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117893","article-title":"Discovery of degrader for FLT3, GSPT1 and IKZF1\/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia","volume":"296","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110289_bb0165","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41422-021-00533-6","article-title":"Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently","volume":"31","author":"Liu","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.bioorg.2026.110289_bb0170","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/biom13050747","article-title":"A new generation of IMiDs as treatments for neuroinflammatory and neurodegenerative disorders","volume":"13","author":"Kopp","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.110289_bb0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12929-023-00907-5","article-title":"Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury","volume":"30","author":"Lecca","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bioorg.2026.110289_bb0180","series-title":"Derivative of Saccharide and Physiologically Active Agent Containing the Same","author":"Yoshikumi","year":"1983"},{"key":"10.1016\/j.bioorg.2026.110289_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126840","article-title":"Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands","volume":"30","author":"Baba","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110289_bb0190","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/poc.3032","article-title":"Substituent effects on the 13C NMR chemical shifts of the imine carbon in N-(4-X\u2013benzylidene)-4-(4-Y\u2013styryl) anilines","volume":"25","author":"Fang","year":"2012","journal-title":"J. Phys. Org. Chem."},{"key":"10.1016\/j.bioorg.2026.110289_bb0195","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0040-4039(00)90486-6","article-title":"The structure of some N-aryl glucosylamines","volume":"5","author":"Capon","year":"1964","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2026.110289_bb0200","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1039\/C9SC00857H","article-title":"Self-promoted and stereospecific formation of N -glycosides","volume":"10","author":"Nielsen","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2026.110289_bb0205","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.bmcl.2016.01.063","article-title":"Carbohydrate-based inducers of cellular stress for targeting cancer cells","volume":"26","author":"Ndombera","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110289_bb0210","doi-asserted-by":"crossref","first-page":"22828","DOI":"10.1039\/c4ra02627f","article-title":"Synthesis and antiproliferative activity of N-glycosyl-3,3-diaryloxindoles","volume":"4","author":"Kleeblatt","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110289_bb0215","series-title":"Clinical Review for Pomalidomide Capsules","author":"FDA, Center for Drug Evaluation and Research","year":"2012"},{"key":"10.1016\/j.bioorg.2026.110289_bb0220","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","article-title":"ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells","volume":"16","author":"Yamamoto","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110289_bb0225","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3390\/jpm11111185","article-title":"Molecular mechanisms of Cereblon-interacting small molecules in multiple myeloma therapy","volume":"11","author":"Costacurta","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.bioorg.2026.110289_bb0230","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110289_bb0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-024-01592-z","article-title":"Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110289_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1264422","article-title":"Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma","volume":"13","author":"Zhuang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110289_bb0245","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110289_bb0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4CRBN ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110289_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110289_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104636","article-title":"Oxaliplatin derived monofunctional triazole-containing platinum (II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer","volume":"107","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110289_bb0265","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/14728220903307509","article-title":"GLUT1 as a therapeutic target in hepatocellular carcinoma","volume":"13","author":"Amann","year":"2009","journal-title":"Expert. Opin. Ther. Tar."},{"key":"10.1016\/j.bioorg.2026.110289_bb0270","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110289_bb0275","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.3390\/cancers14184492","article-title":"CRL4CRBN E3 ligase complex as a therapeutic target in multiple myeloma","volume":"14","author":"Barankiewicz","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110289_bb0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","article-title":"THP-1 cell line: An in vitro cell model for immune modulation approach","volume":"23","author":"Chanput","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.110289_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152428","article-title":"Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activities","volume":"779","author":"Luo","year":"2025","journal-title":"Biochem. Bioph. Res. Co."},{"key":"10.1016\/j.bioorg.2026.110289_bb0290","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1007\/s11357-025-01573-1","article-title":"3-monothiopomalidomide, a new immunomodulatory imide drug (IMiD), blunts inflammation and mitigates ischemic stroke in the rat","volume":"47","author":"Chen","year":"2025","journal-title":"GeroScience"},{"key":"10.1016\/j.bioorg.2026.110289_bb0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12929-025-01150-w","article-title":"Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration","volume":"32","author":"Hsueh","year":"2025","journal-title":"J. Biomed. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:03:17Z","timestamp":1791406997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":59,"alternative-id":["S0045206826008254"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110289","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of molecular glue degrader for treatment of IMiDs-resistant multiple myeloma based on GLUT-mediated tumor targeting strategy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110289"}}